跳至主要内容
临床试验/NCT00680576
NCT00680576已完成1 期

Adolescent Substance Abuse: Progressive Treatment

Oregon Research Institute2 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2008年3月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
140
试验地点
2
主要终点
Urine drug screens

研究概览

简要总结

The purpose of this study is to find out more about how to provide effective further treatment for adolescents who have received six weeks of group therapy for substance-use problems and continue to use drugs. Treatments used in the study include a group therapy (MET/CBT), an individual therapy (CBT), and a family therapy (FFT). The study will look at whether abstinence or a very low level of use is a better guide for deciding whether further treatment is needed, how well different combinations of treatment work to reduce substance use, and whether it is possible to predict in advance which adolescents will respond best to which types of treatment. Study investigators expect that a treatment strategy using what is learned about these issues in the first half of the project to develop an "adaptive" treatment model will work better than a "fixed" treatment to reduce adolescent substance use.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Treatment
盲法
None

入排标准

年龄范围
13 Years 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • 13 to 18 years if age
  • Meet DSM-IV (APA, 1994) diagnostic criteria for substance abuse or dependence
  • Live in the Albuquerque metropolitan area or surrounding communities
  • Sufficient residential stability to permit probable contact at follow-up (e.g., not homeless at time of intake).

排除标准

  • There is evidence of psychotic or organic state of sufficient severity to interfere with the understanding of study instruments and procedures
  • The adolescent is deemed dangerous to self or others during evaluation
  • Services other than outpatient treatment are required for the adolescent (e.g., inpatient, detoxification)
  • Marijuana use is reported as being less than 13% of days in the previous 90 days.

结局指标

主要结局

Urine drug screens

时间窗: Pretx, 6, 14 and 22 weeks, 3 and 6 months after initial treatment session

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验